New COVID-19 drug SIR1-365 tested for safety in hospitalized patients
Disease control
Completed
This early-stage trial tested the safety of an experimental drug called SIR1-365 in 45 hospitalized adults with severe COVID-19. Participants received either the drug or a placebo, and researchers monitored side effects and signs of inflammation. The goal was to see if the drug i…
Phase: PHASE1 • Sponsor: Sironax USA, Inc. • Aim: Disease control
Last updated May 18, 2026 00:23 UTC